What were the results of the ALIAS (Albumin in Acute Ischemic Stroke) part II trial?
The ALIAS (Albumin in Acute Ischemic Stroke) part II trial of high-dose albumin infusion versus placebo in patients with AIS was terminated early for futility. Combined analysis of the ALIAS parts I and II trials demonstrated no difference between groups in 90-day disability.